相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evolving therapeutic landscape of advanced hepatocellular carcinoma
Chen Yang et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2023)
Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical for KRAS mutant cancer
Katrin J. Frank et al.
CELL REPORTS MEDICINE (2022)
Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare
Xiaotao Zhang et al.
CANCER CAUSES & CONTROL (2021)
Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study
Hana Storkanova et al.
SCIENTIFIC REPORTS (2021)
Hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Targeting Oncogenic Src Homology 2 Domain-Containing Phosphatase 2 (SHP2) by Inhibiting Its Protein-Protein Interactions
Sara Bobone et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders
Xiangbo Yang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids
Ke Gong et al.
NATURE COMMUNICATIONS (2021)
Single-cell transcriptomics reveals opposing roles of Shp2 in Myc-driven liver tumor cells and microenvironment
Wendy S. Chen et al.
CELL REPORTS (2021)
Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein
Mingliang Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application
Xinrui Yuan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Targeting mTOR for fighting diseases: A revisited review of mTOR inhibitors
Tian Xu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Cooperation Between Distinct Cancer Driver Genes Underlies Intertumor Heterogeneity in Hepatocellular Carcinoma
Pedro Molina-Sanchez et al.
GASTROENTEROLOGY (2020)
SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer
Hao Chen et al.
ONCOGENE (2020)
Research progress of mTOR inhibitors
Yifan Chen et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
Tian Tian et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Properties of FDA-approved small molecule protein kinase inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Targeting mTOR for cancer therapy
Hui Hua et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Ju Dong Yang et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Inducing and exploiting vulnerabilities for the treatment of liver cancer
Cun Wang et al.
NATURE (2019)
FLT3-ITD Activates RSK1 to Enhance Proliferation and Survival of AML Cells by Activating mTORC1 and eIF4B Cooperatively with PIM or PI3K and by Inhibiting Bad and BIM
Daisuke Watanabe et al.
CANCERS (2019)
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
Dietrich A. Ruess et al.
NATURE MEDICINE (2018)
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
Gabrielle S. Wong et al.
NATURE MEDICINE (2018)
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
Sara Mainardi et al.
NATURE MEDICINE (2018)
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1-and RAS-driven cancers
Robert J. Nichols et al.
NATURE CELL BIOLOGY (2018)
SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models
Carmine Fedele et al.
CANCER DISCOVERY (2018)
A Functional Mammalian Target of Rapamycin Complex 1 Signaling Is Indispensable for c-Myc-Driven Hepatocarcinogenesis
Pin Liu et al.
HEPATOLOGY (2017)
Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity
Seraina Faes et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2017)
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Yiqun Zhang et al.
CANCER CELL (2017)
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Ying-Nan P. Chen et al.
NATURE (2016)
SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal- like and triple-negative breast cancer
Fatimah Matalkah et al.
BREAST CANCER RESEARCH (2016)
PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients
Tao Han et al.
JOURNAL OF HEPATOLOGY (2015)
PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs
Anirudh Prahallad et al.
CELL REPORTS (2015)
Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends
Matthias S. Matter et al.
JOURNAL OF HEPATOLOGY (2014)
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
Chong Sun et al.
CELL REPORTS (2014)
Clinical development of mTOR inhibitors in breast cancer
Cecile Vicier et al.
BREAST CANCER RESEARCH (2014)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Treatment of Hepatocellular Carcinoma: A Systematic Review
Shibo Lin et al.
LIVER CANCER (2012)
Ptpn11/Shp2 Acts as a Tumor Suppressor in Hepatocellular Carcinogenesis
Emilie A. Bard-Chapeau et al.
CANCER CELL (2011)
mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
Vanessa S. Rodrik-Outmezguine et al.
CANCER DISCOVERY (2011)
AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
Christine M. Chresta et al.
CANCER RESEARCH (2010)
Hepatocyte growth factor (HGF) signals through SHP2 to regulate primary mouse myoblast proliferation
Ju Li et al.
EXPERIMENTAL CELL RESEARCH (2009)
Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
Augusto Villanueva et al.
GASTROENTEROLOGY (2008)
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways
Jerome Tamburini et al.
BLOOD (2008)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
MTOR-targeted therapy of cancer with rapamycin derivatives
S Vignot et al.
ANNALS OF ONCOLOGY (2005)
Involvement of SR proteins in mRNA surveillance
Z Zhang et al.
MOLECULAR CELL (2004)
Alcohol and hepatocellular carcinoma
TR Morgan et al.
GASTROENTEROLOGY (2004)
Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling
YM Agazie et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors
T Araki et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes
VK Mootha et al.
NATURE GENETICS (2003)
The immuno suppress ant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation
T Peng et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Activation of hepatocyte growth factor-Met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line
S Yi et al.
NEOPLASIA (2000)
分享论文
